Table 2 Clinical studies of COVID-19 in CF

Cosgriff et al. [18]

Australia, Canada, France, Ireland, Netherlands, New Zealand, UK, USA

Multinational cohort observational

Incidence of COVID-19 in CF was 0.07%, compared to 0.15% in general population

Clinical features of COVID-19 similar in CF and general population

No deaths in cohort

McClenaghan et al. [19]

Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Ireland, Italy, Netherlands, New Zealand, Russia, South Africa, Spain, Sweden, Switzerland, UK, and USA

Multinational cohort observational

Post-transplant individuals (18%) and FEV₁ < 70% were hospitalized at significantly higher rates

7 deaths in cohort (3 post-transplant)

Corvol et al. [20]

France

Prospective cohort

Incidence of COVID-19 in CF was 0.41%, 93% less than general population

Post-transplant individuals (39%) received supplemental oxygen and were hospitalized at significantly higher rates

No deaths in cohort

Mondejar-Lopez et al. [21]

Spain

Retrospective descriptive cohort

Incidence of COVID-19 in CF was 0.32%, compared to 0.49% in general Spanish population

Pediatric subset was not hospitalized, but all adults were

No deaths in cohort

Bain et al. [22]

Argentina, Brazil, Chile, France, Germany, Italy, Russia, South Africa, Spain, Sweden, Switzerland, UK, US

Multinational cohort observational

29% asymptomatic

FEV₁ of hospitalized children significantly lower than non-hospitalized

No deaths directly attributed to COVID-19 in cohort

Moeller et al. [23]

N/A^a

Survey

7 individuals (50%) were hospitalized, with 3 in the PICU

No deaths in sample